News of Note—Merck’s Zostavax, GeoVax and more

In this week's news of note, an appeals court upheld a lower court's decision to throw out a Zostavax injury lawsuit. (Pixabay)

Here is some other vaccine news of note for the week.

> A U.S. Circuit Court of Appeals affirmed a lower court's decision to throw out a Zostavax injury lawsuit against Merck due to the statute of limitations. Court opinion (PDF)

> GeoVax nabbed $300,000 from the NIH’s National Institute of Allergy and Infectious Diseases to support a phase 1 study of its Lassa fever vaccine program. Release

> The University of Washington’s Institute for Protein Design won a $11.3 million grant from the Open Philanthropy Project; about half of it will go toward the development of a universal flu vaccine. GeekWire article

> Using education campaigns to change people’s minds about vaccines is less effective than using behavioral nudges, a new study published in Psychological Science in the Public Interest found. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.